The text has been copied to the clipboard
Journal article

Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.

  • Sun W City of Hope National Medical Center, Duarte, CA, USA. weilisun@coh.org.
  • Malvar J Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Sposto R Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Verma A Primary Children's Hospital, Pediatric Hematology/Oncology, University of Utah, Salt Lake City, UT, USA.
  • Wilkes JJ Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
  • Dennis R Nationwide Children's Hospital, the Ohio State University, Columbus, OH, USA.
  • Heym K Cook Children's Medical Center, Fort Worth, TX, USA.
  • Laetsch TW UT Southwestern Medical Center/ Children's Health, Dallas, TX, USA.
  • Widener M Center for Cancer & Blood Disorders, Children's Hospital Colorado, Aurora, CO, USA.
  • Rheingold SR Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Oesterheld J Levine Children's Hospital at Carolinas Medical Center, Charlotte, NC, USA.
  • Hijiya N Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Sulis ML New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA.
  • Huynh V Children's Hospital Orange County, Hyundai Cancer Institute, Orange, CA, USA.
  • Place AE Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
  • Bittencourt H CHU Sainte-Justine, Universite de Montreal, Montreal, QC, Canada.
  • Hutchinson R C.S Mott Children's Hospital, University of Michigan, Ann Arbor, MI, USA.
  • Messinger Y Children's Hospital of Minnesota, Minneapolis, MN, USA.
  • Chang B Doernbecher Children's Hospital, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Matloub Y Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Ziegler DS Kids Cancer Center, Sydney Children's Hospital, School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.
  • Gardner R Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
  • Cooper T Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
  • Ceppi F Department of Pediatrics, University of Lausanne, Lausanne, Switzerland.
  • Hermiston M Benioff Children's Hospital, University of California, San Francisco, CA, USA.
  • Dalla-Pozza L Cancer Center for Children, The Children's Hospital at Westmead, Westmead, NSW, Australia.
  • Schultz KR BC Children's Hospital and Research Institute, University of British Columbia, Vancouver, BC, Canada.
  • Gaynon P Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Wayne AS Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Whitlock JA The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Show more…
  • 2018-05-06
Published in:
  • Leukemia. - 2018
English The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013. Patient information, treatment, and response were collected. Prognostic factors influencing the complete remission (CR) rate and event-free survival (EFS) were analyzed. The analytic set included 578 salvage treatment attempts among 325 patients. CR rates (mean ± SE) were 51 ± 4% for patients with bone marrow R/R B-ALL who underwent a second salvage attempt, 37 ± 6% for a third attempt, and 31 ± 6% for the fourth through eighth attempts combined. For patients achieving a CR after their second, third, and fourth through eighth attempts, the 2 year EFS was 41 ± 6%, 13 ± 7%, and 27 ± 13% respectively. Our results showed slight improvement when compared to previous studies. This is the largest and most recent study to date that evaluates the outcome of this patient population. Our data will provide detailed reference for the evaluation of new agents being developed for childhood B-ALL.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/78973
Export to…

Statistics

Document views: 59 File downloads:
  • Full-text: 0